Treatment Information

Back

Kidney (Renal) Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Jun 2008

Description:

Patients: This study involved 14 patients with metastatic renal cell carcinoma (kidney cancer). The median age was 70, ranging from 43 to 78 years. Most (86%) had previously been treated with surgery (nephrectomy).

Treatment: Patients were treated with the biological/immunological therapy lenalidomide, which is similar to thalidomide.

Toxicities: Grade 3 fatigue, hyperglycemia, and dyspnea were reported. Grade 4 hyperglycemia was also reported.

Results: The median overall survival was 14 months.

Support: This study was supported by research funds from Celgene, Inc., which markets lenalidomide as Revlimid“.

Correspondence: Dr. Robert J. Motzer





Back